In 843 patients with depressive disorder, pharmacogenomic-guided treatment vs usual care was associated with higher remission and response from weeks 8 to 12 across ages; cognitive (MoCA) gains were age-dependent, sustained in adolescents and absent in the elderly.
RCTn = 843
Li et al. Effectiveness of pharmacogenomic testing across age groups for depressive disorder treatment and its age-dependent effects on cognitive function: A randomized controlled trial